Healthcare News Today
Latest headline on this page:
8 headlines on Healthcare appeared in our news feed in the last 7 days with a measured price reaction attached. 5 of them moved the underlying at least 0.35% in the minutes after the headline crossed. The largest measured reaction was +2.27% over 10 minutes on REGN, after the headline at Oct 30, 06:30:02 ET. 6 more headlines have no measured move.
Price action when the news broke
06:30:02 ET
What moved — last 7 days
| Time | Ticker | Headline | 1 min | Reaction |
|---|---|---|---|---|
| Oct 30, 10:14:34 ET | REGN | Regeneron Pharmaceuticals shares reach a two-year high, up 12%Volume 83.8K shares in 10 min · 11.1× normal | -0.15% | +0.35% · 10m |
| Oct 30, 10:05:44 ET | ABBV | AbbVie (ABBV) plans to focus on smaller bolt-on acquisitions instead of pursuing large transformational mergers and acquisitions. | +0.02% | -0.40% · 10m |
| Oct 30, 07:46:00 ET | ABBV | ABBV Q3: adj. EPS 3.82 vs 3.73 est | — | No measured move |
| Oct 30, 06:31:15 ET | REGN | Regeneron Pharmaceuticals Q3 Adj. EPS $20.07 Beats $16.19 Estimate, Sales $5.116B Beat $4.542B Estimate | 0.00% | +2.16% · 10m |
| Oct 30, 06:30:02 ET | REGN | Regeneron forecasts full-year capital spending of $1,050-$1,100 million | 0.00% | +2.27% · 10m |
| Oct 29, 16:02:51 ET | GILD | Gilead Sciences Inc. (GILD) posted Q3 2026 (USD) revenue of 8.30bln (exp. 7.80bln) and Adj. EPS of 2.55 (exp. 2.19). | — | No measured move |
| Oct 29, 11:40:56 ET | LLY | Eli Lilly reported $303 million in asset impairment, restructuring and other special charges for the three months ended Sept. 30 in an SEC filing | +0.04% | +0.36% · 10m |
| Oct 29, 11:00:10 ET | PFE | Edison Scientific and Pfizer agree to accelerate research and development | +0.05% | +0.08% · 10m |
| Oct 29, 09:44:03 ET | LLY | Walmart, Eli Lilly and three other companies opt out of OKX and ICE tokenized-stock plans, raising objections from more than 50% of the original roster | +0.07% | +0.49% · 10m |
| Oct 29, 07:06:43 ET | LLY | According to a presentation, Eli Lilly (LLY) says its obesity medicines are being selected by 7 out of 10 patients through the government’s Medicare programme. | — | No measured move |
| Oct 29, 06:59:00 ET | BMY | BMY Q3: adj. EPS 1.35 vs 1.21 est | — | No measured move |
| Oct 29, 06:48:17 ET | LLY | Eli Lilly and Company (LLY) Q3 2026 (USD): adj. EPS 7.48 (exp. 5.68), Revenue 24.4bln (exp. 22.58bln); Mounjaro 10.7bln (exp. 9.95bln), Zepbound 5.3bln (exp. 5bln) Current FY Rev. 91-92bln (exp. 88.82bln), adj. EPS 35-36 (prev. view 35.5-36.5, exp. 33.93) | — | No measured move |
| Oct 29, 06:30:02 ET | MRK | $MRK Merck & Co reports Q3 Adj. EPS of $2.49, est. $2.07, and revenue of $18.09B, est. $17.31B. Keytruda revenue was $8.60B, est. $8.38B; Gardasil revenue was $2.00B, est. $1.75B; Keytruda Qlex revenue was $830M, est. $699.6M; Winrevair revenue was $694M, est. $643.1M; and Animal Health sales were $1.68B, est. $1.69B. Merck & Co sees FY sales of $66.8B to $67.3B, saw $66.3B to $67.3B, and FY Adj. EPS of $2.77 to $2.82, saw $2.66 to $2.76. It still sees FY Adj. gross margin about 81%, est. 81%. | — | No measured move |
| Oct 28, 11:44:00 ET | LLY | ADDF’s Diagnostics Accelerator licenses its longitudinal SpeechDx speech-and-biomarker dataset to Eli Lilly for Alzheimer’s research | -0.03% | -0.02% · 10m |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.
Our analysis
EQT Agrees to Buy Qiagen for €46.50 a Share, Six Years After Thermo Fisher's Bid Failed
Thursday, Oct 22, 2026 · EQT's private equity arm agreed on October 21, 2026 to buy Qiagen for €46.50 a share in cash, about €10.8 billion including debt. It needs only …
Medpace Q3 2026 Earnings: Bookings Rise and the Profit Forecast Goes Up as Revenue Growth Slows
Thursday, Oct 22, 2026 · Medpace beat third-quarter EPS forecasts at $4.84, raised its 2026 EPS outlook and replaced its buyback with a $1.0 billion plan. Revenue growth slowed to 8.5%, …
Why Danaher Stock Rose After Q3 2026: A Higher Profit Forecast and a Lower Growth Forecast
Wednesday, Oct 21, 2026 · Danaher beat with adjusted EPS of $2.11 and raised its 2026 range to $8.57 to $8.62 while cutting its core growth forecast to about 2.5%. The …
Abbott to Spin Off Its $8.5 Billion Nutrition Business as Q3 2026 Earnings Match Forecasts
Wednesday, Oct 21, 2026 · Abbott plans to spin off the maker of Similac and Ensure by the end of 2027. Third-quarter adjusted EPS of $1.42 matched forecasts, and the stock …
Why Roivant Stock Rose: Brepocitinib Met Its Goal in Both Phase 3 Uveitis Trials
Wednesday, Oct 21, 2026 · Roivant and Priovant said brepocitinib met the main goal of both CLARITY Phase 3 trials in non-infectious uveitis, with median time to treatment failure above 48 …
Why Intuitive Surgical Stock Fell After Q3 2026 Earnings: U.S. Procedures Slowed and Instrument Prices Will Drop
Wednesday, Oct 21, 2026 · Intuitive Surgical grew revenue 22% in the third quarter of 2026, but U.S. da Vinci procedures grew only 10% and management set out a 3% to …
Why Intuitive Surgical (ISRG) Stock Fell 11.76% in 10 Minutes After Q3 Earnings on Oct 20, 2026
Tuesday, Oct 20, 2026 · Adjusted EPS of $3.00 came in above the $2.64 estimate; revenue of $3.05 billion came in above the $2.91 billion estimate.
UnitedHealth's Q3 2026 beat leaned on a $610 million reserve release, and the stock gave back a 5% opening gain
Tuesday, Oct 13, 2026 · Adjusted EPS of $4.69 beat the $4.14 consensus and the 2026 outlook rose to at least $20.50, but the stock closed down 0.20%.
2027 Medicare Advantage star ratings: Humana returns to 95% of members in 4-star plans as Alignment's main contract falls to 3.5 stars, October 8, 2026
Thursday, Oct 8, 2026 · Humana went from about 20% of members in four-star plans to about 95%, Aetna slipped to more than 69%, and Alignment's California HMO, three quarters of …
argenx (ARGX) stock falls after the Phase 3 UNITY trial of Vyvgart in Sjögren's disease is stopped for futility, October 8, 2026
Thursday, Oct 8, 2026 · An interim analysis found UNITY could not meet its primary endpoint. The shares were down 15.7% in Brussels by mid-morning, though analysts had given the trial …
Why Fresenius Medical Care shares fell 6.85%: the board replaced CEO Helen Giza with Shervin Korangy
Wednesday, Oct 7, 2026 · The Supervisory Board unanimously named former BVI Medical chief Shervin J. Korangy CEO from October 12, 2026. Helen Giza leaves after almost four years, and the …
Why Was Abbott Stock Down on Oct 22, 2026?
Thursday, Oct 22, 2026 · Abbott fell 1.89% on October 21, 2026 after it lowered its 2026 sales growth forecast to about 6.0% and announced a spin-off of its $8.5 billion …
Why Was ENvue Medical Stock Down on Aug 28, 2026?
Friday, Aug 28, 2026 · FEED fell before its reverse split became effective, showing that the market repriced the signal rather than the mechanical share conversion.
Why Was Pluri Stock Up on Aug 27, 2026?
Thursday, Aug 27, 2026 · PLUR rose on an equity offering because the $1.50 deal price stood above the pre-event market, though measured volume was thin.
Why Was Kazia Therapeutics Stock Down on Aug 27, 2026?
Thursday, Aug 27, 2026 · Kazia's initial offering announcement removed pricing certainty; the next-day terms separated $40 million of upfront proceeds from contingent warrants.
Why Was Celularity Stock Up on Aug 27, 2026?
Thursday, Aug 27, 2026 · Celularity's manufacturing collaboration produced a two-stage repricing, while the headline purchase opportunity remains conditional and multi-year.
Why Was Quoin Pharmaceuticals Stock Up on Aug 28, 2026?
Friday, Aug 28, 2026 · QNRX rose after Quoin paired encouraging early QRX003 data with financing designed to extend its development runway.
Why Was Costco Stock Moving on Aug 18, 2026?
Tuesday, Aug 18, 2026 · Costco is putting its name on Medicare plans with SCAN Health Plan — and federal rules bar the one thing it would most want to include.
Cardinal Health Beat by Half a Dollar, Added $5 Billion to Its Buyback, and Hit a 52-Week High
Tuesday, Aug 11, 2026 · Cardinal Health closed fiscal 2026 with a fourth quarter that beat the profit estimate by a wide margin — non-GAAP EPS of $2.91 against a $2.42 …
Organogenesis Revenue Fell 58% After a CMS Reimbursement Change Gutted Its Wound-Care Business
Friday, Aug 7, 2026 · Organogenesis reported Q2 2026 net revenue of $42.8 million, down 58% from $100.8 million a year earlier, as a CMS and Medicare reimbursement change disrupted its …
Why Was Envista Stock Up on Aug 6, 2026?
Thursday, Aug 6, 2026 · Envista is trading higher today, recovering part of yesterday's 14.3% drop that followed a quarter where the dental-products company beat both earnings and revenue estimates and …
Envista Beat Estimates and Raised Its Outlook. The Stock Fell 14% Anyway
Thursday, Aug 6, 2026 · Envista, the dental-products company behind DEXIS, Kerr, Nobel Biocare and Ormco, beat both earnings and revenue estimates on August 5, 2026 and raised its full-year outlook. …
Why Was Sight Sciences Stock Down on Aug 5, 2026?
Wednesday, Aug 5, 2026 · SGHT is down on the session with no new company-specific headline today. The move follows an FDA-clearance pop the day before that has now fully unwound.
Sight Sciences Jumped 18% After Hours on an FDA Clearance. A Day Later It Was Below Where It Started.
Wednesday, Aug 5, 2026 · Shares of the glaucoma-device maker spiked 18.5% within a minute of an FDA 510(k) clearance for its next-generation OMNI Ultra system. By the next session, the …
Why Was Amwell Stock Up on Aug 5, 2026?
Wednesday, Aug 5, 2026 · A beat on both lines, but the real signal is a second straight quarter of narrowing losses on the path to positive cash flow.
AdaptHealth Q2 2026: A 17.6% Guidance Cut, and a GAAP Loss the Adjusted Number Didn't Show
Tuesday, Aug 4, 2026 · AdaptHealth reported second-quarter 2026 results on August 4, 2026.
Why Was AdaptHealth Stock Down on Aug 4, 2026?
Tuesday, Aug 4, 2026 · AdaptHealth's adjusted EPS was $0.08. Its GAAP EPS was a $0.99 loss. The stock fell 38.04% on the guidance cut underneath both.
Integer Holdings (ITGR): KKR Reported Near $4.3 Billion Buyout at $127 a Share
Saturday, Aug 1, 2026 · On July 31, 2026, the Wall Street Journal reported KKR was nearing a deal to acquire Integer Holdings at $127 a share, about $4.3 billion.
Why Was Integer Holdings Stock Up on Aug 1, 2026?
Saturday, Aug 1, 2026 · Integer Holdings jumped 20% after the Wall Street Journal reported KKR is nearing a deal to buy the medical-device manufacturer at $127 a share.